Review of possible mechanisms of radiotherapy resistance in cervical cancer

Front Oncol. 2023 Aug 22:13:1164985. doi: 10.3389/fonc.2023.1164985. eCollection 2023.

Abstract

Radiotherapy is one of the main treatments for cervical cancer. Early cervical cancer is usually considered postoperative radiotherapy alone. Radiotherapy combined with cisplatin is the standard treatment for locally advanced cervical cancer (LACC), but sometimes the disease will relapse within a short time after the end of treatment. Tumor recurrence is usually related to the inherent radiation resistance of the tumor, mainly involving cell proliferation, apoptosis, DNA repair, tumor microenvironment, tumor metabolism, and stem cells. In the past few decades, the mechanism of radiotherapy resistance of cervical cancer has been extensively studied, but due to its complex process, the specific mechanism of radiotherapy resistance of cervical cancer is still not fully understood. In this review, we discuss the current status of radiotherapy resistance in cervical cancer and the possible mechanisms of radiotherapy resistance, and provide favorable therapeutic targets for improving radiotherapy sensitivity. In conclusion, this article describes the importance of understanding the pathway and target of radioresistance for cervical cancer to promote the development of effective radiotherapy sensitizers.

Keywords: cervical cancer; mechanism; radiotherapy; radiotherapy resistance; radiotherapy sensitivity.

Publication types

  • Review

Grants and funding

This research was supported by the Science and Technology Plan Project of Chengguan District, Lanzhou (award number: No. 2020-2-2-5), the Lanzhou Innovation and Entrepreneurship Talent Project (award number: 2017-RC-23/2020-RC-113), the Key R&D Program of Science and Technology Department of Gansu Province (No. 20YF8FA116), the Talent innovation and venture project of Lanzhou city (No. 2021-RC-125; 2020-RC-113), the Heavy Ion Research Facility in Lanzhou (HIRFL), the authorized project of Lanzhou KejinTaiji Corporation, Ltd (No. BMP-B-02-002), the Project supported by the China Foundation for International Medical Exchange (No. Z-2017-24-2108), the National Natural Science Foundation of China (No. 81860535), and the Guizhou Innovation and Entrepreneurship Foundation for High-level Overseas Talent (No [2019] 03).